|
Mar 15
|
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
|
|
Mar 15
|
Bristol Myers Squibb (BMY) Stock Moves -0.29%: What You Should Know
|
|
Mar 15
|
UPDATE 2-US FDA panel unanimously backs expanded use of J&J's CAR-T therapy
|
|
Mar 15
|
20 States with the Highest Cancer Rates
|
|
Mar 15
|
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
|
|
Mar 15
|
Bristol Myers cell therapy wins first-of-its-kind approval
|
|
Mar 15
|
CORRECTED-UPDATE 2-US FDA expands use of Bristol Myers' cancer therapy (March 14)
|
|
Mar 15
|
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
|
|
Mar 14
|
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
|
|
Mar 13
|
UPDATE 3-US FDA staff raise concerns over data from J&J, Bristol's CAR-T therapies
|
|
Mar 13
|
Analysts on Wall Street Lower Ratings for These 10 Stocks
|
|
Mar 13
|
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies
|
|
Mar 13
|
11 Oversold Healthcare Stocks To Buy Right Now
|
|
Mar 11
|
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
|
|
Mar 11
|
15 Best ETFs To Buy Now
|
|
Mar 8
|
Bristol-Myers Squibb (NYSE:BMY) Will Pay A Dividend Of $0.60
|
|
Mar 7
|
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
|
|
Mar 7
|
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
|
|
Mar 7
|
Amgen (AMGN) Down 6.5% Since Last Earnings Report: Can It Rebound?
|
|
Mar 6
|
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
|